Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts

Published:2012-10 Issue:2-3 Volume:27 Page:107-113
ISSN:0966-3274
Container-title:Transplant Immunology
language:en
Short-container-title:Transplant Immunology

Author:

Smith R. Neal,Malik Fahim,Goes Nelson,Farris Alton B.,Zorn Emmanuel,Saidman Susan,Tolkoff-Rubin Nina,Puri Sonika,Wong Waichi

Publisher

Elsevier BV

Subject

Transplantation,Immunology,Immunology and Allergy

Reference41 articles.

1. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN');Solez;Am J Transplant,2007

2. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries;Mauiyyedi;J Am Soc Nephrol,2001

3. Antibody-mediated rejection criteria—An addition to the Banff 97 classification of renal allograft rejection;Racusen;Am J Transplant,2003

4. Improved graft survival after renal transplantation in the United States, 1988 to 1996;Hariharan;N Engl J Med,2000

5. The pathogenesis and treatment of chronic allograft nephropathy;Li;Nat Rev Nephrol,2009

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe;Transplant International;2023-07-17

2. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design;Trials;2022-12-22

3. Photopheresis Abates the Anti-HLA Antibody Titer and Renal Failure Progression in Chronic Antibody-Mediated Rejection;Biology;2021-06-18

4. Chronic-active Antibody-mediated Rejection: To Belatacept or Not, That Is the HOT Question;Transplantation;2020-07-22

5. Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation;Clinical Transplantation;2020-06-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3